Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 Tat activation-response RNA decoy

被引:37
作者
Browning, CM
Cagnon, L
Good, PD
Rossi, J
Engelke, DR
Markovitz, DM
机构
[1] Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Med Ctr, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA
[4] City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol Mol, Duarte, CA 91010 USA
关键词
D O I
10.1128/JVI.73.6.5191-5195.1999
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Tat activation-response region (TAR) decoys have been developed for use in gene therapy for people infected with human immunodeficiency virus type 1 (HIV-1). When a TAR RNA decoy is overexpressed, it will bind Tat, thus leaving less of this crucial protein to bind to and activate the natural transcriptional promoter of HIV-1. Previous TAR decoy constructs have used HIV-I TAR. However, recent epidemiological and biological data began to suggest that the TAR region from the human immunodeficiency virus type 2 (HIV-2) may suppress HIV-1 transcription and hence replication. We created a vector which overexpresses TAR-2 under the control of the human U6 small nuclear RNA gene promoter and here show that the U6-TAR-2 decoy construct potently inhibits both HIV-2 and HIV-1 gene expression. Further, this decoy construct is able to markedly suppress HIV-1 replication. Thus, we have directly proven that TAR-2 can suppress HIV-1 replication and suggest that the HIV-2 TAR decoy may prove useful for combating HIV-1 infection.
引用
收藏
页码:5191 / 5195
页数:5
相关论文
共 44 条
  • [11] THE BASIC RNA-BINDING DOMAIN OF HIV-2 TAT CONTRIBUTES TO PREFERENTIAL TRANSACTIVATION OF A TAR2-CONTAINING LTR
    CHANG, YN
    JEANG, KT
    [J]. NUCLEIC ACIDS RESEARCH, 1992, 20 (20) : 5465 - 5472
  • [12] The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II
    Cujec, TP
    Okamoto, H
    Fujinaga, K
    Meyer, J
    Chamberlin, H
    Morgan, DO
    Peterlin, BM
    [J]. GENES & DEVELOPMENT, 1997, 11 (20) : 2645 - 2657
  • [13] THE TRANSACTIVATOR GENE OF THE HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-III IS REQUIRED FOR REPLICATION
    DAYTON, AI
    SODROSKI, JG
    ROSEN, CA
    GOH, WC
    HASELTINE, WA
    [J]. CELL, 1986, 44 (06) : 941 - 947
  • [14] THE SPECIFICITY OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2 TRANSACTIVATOR IS DIFFERENT FROM THAT OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    EMERMAN, M
    GUYADER, M
    MONTAGNIER, L
    BALTIMORE, D
    MUESING, MA
    [J]. EMBO JOURNAL, 1987, 6 (12) : 3755 - 3760
  • [15] HIV-1 regulatory/accessory genes: Keys to unraveling viral and host cell biology
    Emerman, M
    Malim, MH
    [J]. SCIENCE, 1998, 280 (5371) : 1880 - 1884
  • [16] FUNCTIONAL-ANALYSIS OF THE TAT TRANS-ACTIVATOR OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-2
    FENRICK, R
    MALIM, MH
    HAUBER, J
    LE, SY
    MAIZEL, J
    CULLEN, BR
    [J]. JOURNAL OF VIROLOGY, 1989, 63 (12) : 5006 - 5012
  • [17] Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
    Finzi, D
    Hermankova, M
    Pierson, T
    Carruth, LM
    Buck, C
    Chaisson, RE
    Quinn, TC
    Chadwick, K
    Margolick, J
    Brookmeyer, R
    Gallant, J
    Markowitz, M
    Ho, DD
    Richman, DD
    Siliciano, RF
    [J]. SCIENCE, 1997, 278 (5341) : 1295 - 1300
  • [18] THE TRANSACTIVATOR GENE OF HTLV-III IS ESSENTIAL FOR VIRUS-REPLICATION
    FISHER, AG
    FEINBERG, MB
    JOSEPHS, SF
    HARPER, ME
    MARSELLE, LM
    REYES, G
    GONDA, MA
    ALDOVINI, A
    DEBOUK, C
    GALLO, RC
    WONGSTAAL, F
    [J]. NATURE, 1986, 320 (6060) : 367 - 371
  • [19] GARCIAMARTINEZ LF, 1995, J MOL BIOL, V254, P350
  • [20] GAYNOR RB, 1995, CURR TOP MICROBIOL, V193, P51